Skip to content
ClinCalc Pro
Menu
Biguanide — Gestational Diabetes / PCOS

Metformin (Gestational Diabetes / PCOS)

Brand names: Glucophage

Metformin is an oral biguanide antihyperglycaemic used in obstetrics and gynaecology for gestational diabetes and as an insulin-sensitising agent in polycystic ovary syndrome, including to support ovulation and reduce metabolic risk.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity, lowering circulating glucose and insulin without directly stimulating insulin secretion.

Prescribing in practice

  • Metformin crosses the placenta but is widely used in pregnancy and lactation; it does not cause maternal hypoglycaemia when used alone, though insulin may still be required if glycaemic targets are not met.
  • Withhold around procedures involving iodinated contrast and during acute intercurrent illness, dehydration or significant renal impairment because of the risk of lactic acidosis.
  • Gastrointestinal upset is common on initiation; gradual dose titration and taking it with food improve tolerability.

Monitoring

Monitor capillary blood glucose against pregnancy targets, renal function, and in PCOS the relevant metabolic and ovulatory response.

Counselling the patient

  • Take with or just after meals to reduce nausea, bloating and diarrhoea.
  • It improves blood sugar control but does not replace dietary and lifestyle measures.
  • Report persistent vomiting, dehydration or unusual muscle pain and stop temporarily if seriously unwell.

Evidence & guidelines

NICE guidance supports metformin (alone or with insulin) as a first-line option for gestational diabetes, and the MiG trial demonstrated comparable perinatal outcomes to insulin.

Reference: NICE NG3 (Diabetes in Pregnancy); MiG Trial (Rowan et al. NEJM 2008); ESHRE/ASRM PCOS Guidelines 2023; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.